Current News

Contact | Print version | Send article | RSS feed

Aeras commits further USD$5 million to existing TB research agreement with Crucell

09 Mar 2007 - Crucell N.V. announced it will receive up to USD$5 million from Rockville, Maryland-headquartered Aeras Global TB Vaccine Foundation to support the advanced development of the candidate AdVac-based tuberculosis vaccine.
 
"This technology, which is based on one of the most advanced vector delivery systems for induction of cellular immunity, represents an important part of the portfolio of vaccines we are developing against tuberculosis," said Dr. Jerald C. Sadoff, President & CEO of Aeras Global TB Vaccine Foundation. "We are excited about our continued collaboration with Crucell to support the process development and manufacturing of this promising vaccine candidate."
 
In March 2004, Aeras and Crucell entered into a collaborative agreement for the development of a PER.C6® and AdVac®-based TB vaccine. The vaccine entered the phase I clinical trial in October 2006."